NCT02617134View on ClinicalTrials.gov

CAR-T Cell Immunotherapy in MUC1 Positive Solid Tumor

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

November 30, 2017

Study Completion Date

November 30, 2018

Conditions
Malignant Glioma of BrainColorectal CarcinomaGastric Carcinoma
Interventions
BIOLOGICAL

anti-MUC1 CAR-T cells

Trial Locations (1)

215123

RECRUITING

PersonGen Biomedicine (Suzhou) Co., Ltd., Suzhou

Sponsors
All Listed Sponsors
collaborator

The First People's Hospital of Hefei

OTHER

collaborator

Hefei Binhu Hospital

OTHER

lead

PersonGen BioTherapeutics (Suzhou) Co., Ltd.

INDUSTRY

NCT02617134 - CAR-T Cell Immunotherapy in MUC1 Positive Solid Tumor | Biotech Hunter | Biotech Hunter